sulfasalazine has been researched along with 2019 Novel Coronavirus Disease in 13 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulfasalazine was indicated in two cases." | 3.01 | Reactive arthritis occurring after COVID-19 infection: a narrative review. ( Abbes, M; Dhahri, R; Gharsallah, I; Louzir, B; Mehmli, T; Metoui, L; Slouma, M, 2023) |
| "There is paucity of data on extended dosing interval between two doses of AZD1222 (AstraZeneca) in patients with Autoimmune Rheumatic Diseases (AIRD)." | 1.72 | Effectiveness of delayed second dose of AZD1222 vaccine in patients with autoimmune rheumatic disease. ( Ahmed, S; Benny, J; Cherian, S; Mehta, P; Panthak, A; Paul, A; Shenoy, P, 2022) |
| "The majority of patients had Crohn's disease (CD) (60%) and most of them were in clinical remission." | 1.62 | COVID-19 in IBD: The experience of a single tertiary IBD center. ( Belluzzi, A; Calabrese, C; Calandrini, L; Decorato, A; Dussias, N; Filippone, E; Gionchetti, P; Laureti, S; Melotti, L; Peruzzi, G; Poggioli, G; Privitera, H; Rizzello, F; Rottoli, M; Salice, M; Scaioli, E; Siniscalchi, A, 2021) |
| "The impact of Coronavirus disease 2019 (COVID-19) on patients with inflammatory bowel disease (IBD) is unknown." | 1.56 | Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. ( Brenner, EJ; Colombel, JF; Gearry, RB; Kaplan, GG; Kappelman, MD; Kissous-Hunt, M; Lewis, JD; Ng, SC; Rahier, JF; Reinisch, W; Ruemmele, FM; Steinwurz, F; Underwood, FE; Ungaro, RC; Zhang, X, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 13 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ungaro, RC | 3 |
| Brenner, EJ | 3 |
| Agrawal, M | 1 |
| Zhang, X | 3 |
| Kappelman, MD | 3 |
| Colombel, JF | 3 |
| Slouma, M | 1 |
| Abbes, M | 1 |
| Mehmli, T | 1 |
| Dhahri, R | 1 |
| Metoui, L | 1 |
| Gharsallah, I | 1 |
| Louzir, B | 1 |
| Mehta, P | 1 |
| Paul, A | 1 |
| Ahmed, S | 1 |
| Cherian, S | 1 |
| Panthak, A | 1 |
| Benny, J | 1 |
| Shenoy, P | 1 |
| G S Saad, C | 1 |
| S R Silva, M | 1 |
| Sampaio-Barros, PD | 1 |
| C B Moraes, J | 1 |
| G Schainberg, C | 1 |
| Gonçalves, CR | 1 |
| Shimabuco, AY | 1 |
| Aikawa, NE | 1 |
| F N Yuki, E | 1 |
| G Pasoto, S | 1 |
| V K Kupa, L | 1 |
| K Aoyama, R | 1 |
| S R Araujo, C | 1 |
| Silva, CA | 1 |
| Medeiros-Ribeiro, AC | 1 |
| Bonfa, E | 1 |
| Armağan, B | 1 |
| Atalar, E | 1 |
| Güven, SC | 1 |
| Özdemir, B | 1 |
| Konak, HE | 1 |
| Akyüz Dağlı, P | 1 |
| Erden, A | 1 |
| Gök, K | 1 |
| Maraş, Y | 1 |
| Doğan, İ | 1 |
| Küçükşahin, O | 1 |
| Erten, Ş | 1 |
| Omma, A | 1 |
| Barrett, R | 2 |
| Lin, SX | 1 |
| Culliford, D | 1 |
| Fraser, S | 1 |
| Edwards, CJ | 1 |
| Gearry, RB | 1 |
| Kaplan, GG | 1 |
| Kissous-Hunt, M | 1 |
| Lewis, JD | 1 |
| Ng, SC | 1 |
| Rahier, JF | 1 |
| Reinisch, W | 1 |
| Ruemmele, FM | 2 |
| Steinwurz, F | 1 |
| Underwood, FE | 1 |
| Pers, YM | 1 |
| Padern, G | 1 |
| Pigneur, B | 1 |
| Focht, G | 1 |
| Turner, D | 1 |
| Balconi, SN | 1 |
| Lopes, NT | 1 |
| Luzzatto, L | 1 |
| Bonamigo, RR | 1 |
| Rizzello, F | 1 |
| Calabrese, C | 1 |
| Salice, M | 1 |
| Calandrini, L | 1 |
| Privitera, H | 1 |
| Melotti, L | 1 |
| Peruzzi, G | 1 |
| Dussias, N | 1 |
| Belluzzi, A | 1 |
| Scaioli, E | 1 |
| Decorato, A | 1 |
| Siniscalchi, A | 1 |
| Filippone, E | 1 |
| Laureti, S | 1 |
| Rottoli, M | 1 |
| Poggioli, G | 1 |
| Gionchetti, P | 1 |
| Han, N | 1 |
| Hwang, W | 1 |
| Tzelepis, K | 1 |
| Schmerer, P | 1 |
| Yankova, E | 1 |
| MacMahon, M | 1 |
| Lei, W | 1 |
| M Katritsis, N | 1 |
| Liu, A | 1 |
| Felgenhauer, U | 1 |
| Schuldt, A | 1 |
| Harris, R | 1 |
| Chapman, K | 1 |
| McCaughan, F | 1 |
| Weber, F | 1 |
| Kouzarides, T | 1 |
| Roy, S | 1 |
| Sheikh, SZ | 1 |
| Furey, TS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDS[NCT04754698] | Phase 4 | 2,067 participants (Anticipated) | Interventional | 2021-02-09 | Active, not recruiting | ||
| Monitoring Serologic Response to SARS-COV-2 / Coronavirus Disease 2019 (COVID-19) in Children, Adolescents, and Young Adults Receiving Biologic Therapies (RECONN)[NCT04838834] | 472 participants (Actual) | Observational | 2020-05-15 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sulfasalazine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Reactive arthritis occurring after COVID-19 infection: a narrative review.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Reactive; COVID-19; Female; Humans; Male; | 2023 |
1 trial available for sulfasalazine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Axial Spondyloarthritis; COVID-19; COVID-19 Vaccines; Fe | 2023 |
11 other studies available for sulfasalazine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry.
Topics: Adrenal Cortex Hormones; COVID-19; Humans; Inflammatory Bowel Diseases; Mesalamine; Registries; SARS | 2022 |
Effectiveness of delayed second dose of AZD1222 vaccine in patients with autoimmune rheumatic disease.
Topics: Autoimmune Diseases; ChAdOx1 nCoV-19; COVID-19; COVID-19 Vaccines; Humans; Methotrexate; Mycophenoli | 2022 |
Effects of sulfasalazine in axial spondyloarthritis on COVID-19 outcomes: real-life data from a single center.
Topics: Axial Spondyloarthritis; Biological Products; COVID-19; Female; Humans; Male; Middle Aged; Retrospec | 2023 |
Impact of the COVID-19 pandemic on prescription refills for immune-mediated inflammatory disorders: a time series analysis (January 2019 to January 2021) using the English Prescribing Dataset.
Topics: Azathioprine; Communicable Disease Control; COVID-19; Drug Prescriptions; Humans; Hydroxychloroquine | 2022 |
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
Topics: Adrenal Cortex Hormones; Adult; Aged; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19 | 2020 |
Revisiting the cardiovascular risk of hydroxychloroquine in RA.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antimalarials; Arthritis, Rheumatoid; Azithromycin; Ca | 2020 |
Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases.
Topics: Adolescent; Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Co | 2021 |
Detection of SARS-CoV-2 in a case of DRESS by sulfasalazine: could there be a relationship with clinical importance?
Topics: COVID-19; Drug Hypersensitivity Syndrome; Female; Humans; SARS-CoV-2; Sulfasalazine; Young Adult | 2021 |
COVID-19 in IBD: The experience of a single tertiary IBD center.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Biological Products; | 2021 |
Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Neural Networks, Co | 2021 |
A machine learning approach identifies 5-ASA and ulcerative colitis as being linked with higher COVID-19 mortality in patients with IBD.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, P | 2021 |